Attached files

file filename
EX-21.1 - EX-21.1 - Timber Pharmaceuticals, Inc.bpmx-20180131ex211fcfbdf.htm
EX-31.2 - EX-31.2 - Timber Pharmaceuticals, Inc.bpmx-20180131ex31237d61e.htm
EX-31.1 - EX-31.1 - Timber Pharmaceuticals, Inc.bpmx-20180131ex3119c0b86.htm
EX-23.1 - EX-23.1 - Timber Pharmaceuticals, Inc.bpmx-20180131ex2318ef72b.htm
10-K - 10-K - Timber Pharmaceuticals, Inc.bpmx-20180131x10k.htm

EXHIBIT 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES‑OXLEY ACT OF 2002

 

In connection with the Annual Report of BioPharmX Corporation (the “Company”) on Form 10‑K for the fiscal year ended January 31, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, in the capacities and on the date indicated below, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes‑Oxley Act of 2002, that to the best of their knowledge:

 

1.

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and

 

2.

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: April 26, 2018

 

 

 

 

/s/ ANJA KRAMMER

 

Anja Krammer

 

President (Principal Executive Officer)

 

 

 

/s/ Greg Kitchener

 

Greg Kitchener

 

Chief Financial Officer (Principal Financial Officer and

 

Principal Accounting Officer)

 

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.